The biosimilar Remsima (infliximab), a generic version of Johnson & Johnson/Merck & Co. Inc.’s Remicade, became the fifth best-selling product for Finland’s Orion Pharma during the first half of 2016, achieving sales of €22m (+161%) and accounting for 4% of Orion’s sales revenues of €535m in the half.
“Orion continued to enjoy winning some tenders here in Scandinavia, where we sell the product,” commented company CEO Timo Lappalainen...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?